The Insulin agreement includes $57.5m in potential product development and sales milestone payments to Emisphere, of which $5m will be payable upon signing, as well as royalties on sales
Emisphere’s drug delivery technology platform, known as the Eligen Technology, uses proprietary, synthetic chemical compounds, known as Emisphere delivery agents, sometimes called carriers.
The technology can be applied to the oral route of administration as well as other delivery pathways such as buccal, rectal, inhalation, intra-vaginal or transdermal
Emisphere claims Eligen Technology makes it possible to deliver a therapeutic molecule without altering its chemical form or biological integrity.
Novo Nordisk Diabetes Research Unit senior vice president Peter Kurtzhals said this is an encouraging agreement on a technology for oral administration of proteins.